Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals

A mannan, immunocompromised technology, applied in drug combinations, medical preparations containing active ingredients, peptide/protein components, etc.

Inactive Publication Date: 2007-01-24
斯蒂芬·蒂尔 +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

MBL deficiency is associated with susceptibility to various infections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals
  • Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] To date, MBL has been used to treat MBL deficiency, which is defined as any level below 50 ng / ml, or more often below 10 ng / ml serum, a cut-off level typically associated with various MBL detection assays. The level of sensitivity was consistent, so this level was set at a level of MBL that was substantially undetectable by various assays in the prior art.

[0033] The present invention shows that infection in immunocompromised individuals can be prevented and / or treated independently of their serum MBL levels. Especially when MBL is administered in immunocompromised individuals whose MBL levels exceed 50 ng / ml serum, infection in these individuals can be prevented. In addition, individuals with MBL levels greater than 75 ng / ml serum may require treatment, such as individuals with MBL levels greater than 100 ng / ml serum, and individuals with MBL levels greater than 150 ng / ml serum.

[0034] Infections can also be treated with MBL by administering MBL to such individual...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising at least one mannan-binding lectin. Use of a composition of (MBL) subunit) in the preparation of a medicament for preventing and / or treating infections. In particular, the present invention relates to the prevention and / or treatment of infections in immunocompromised individuals; and / or in immunocompromised susceptible individuals due to medical treatments. The present invention is particularly suitable for the prevention and / or treatment of infections in neutropenic patients and / or patients receiving or about to receive chemotherapy or similar treatments. Such individuals may be treated regardless of their serum MBL levels, but prophylaxis and / or treatment has been shown to be advantageous, particularly in patients with serum MBL levels between 50 ng / ml and 500 ng / ml.

Description

[0001] This application is a branch of the patent application with the application number 00809714.3, the application date is May 10, 2000, and the invention title is "New significance of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals". case application. field of invention [0002] The present invention relates to the use of subunits and oligomers of mannan-binding lectin (MBL) in the prophylactic and / or curative treatment of immunocompromised individuals. Background of the invention [0003] Multiple groups of lectins, carbohydrate-binding proteins, are known in the human body. One of these groups is the C-type lectins. C-type lectins contain a calcium-dependent carbohydrate recognition domain (C-type CRD) 1 . Mannan-binding lectin (MBL) (synonym for mannose-binding lectin), mannan-binding protein, or mannose-binding protein (MBP) belongs to the subgroup of C-type lectins called collectins. group because these soluble proteins consist of s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P31/00A61P37/04
Inventor 斯蒂芬·蒂尔詹斯·C·詹斯尼厄斯
Owner 斯蒂芬·蒂尔
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com